• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Ther . Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza

tetano

Editor, Senior Moderator
Mol Ther


. 2023 Mar 16;S1525-0016(23)00133-8.
doi: 10.1016/j.ymthe.2023.03.012. Online ahead of print.
Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza


Ina Charlotta Werninghaus[SUP] 1 [/SUP], Daniëla Maria Hinke[SUP] 2 [/SUP], Even Fossum[SUP] 2 [/SUP], Bjarne Bogen[SUP] 3 [/SUP], Ranveig Braathen[SUP] 1 [/SUP]



Affiliations

Abstract

Conventional influenza vaccines focus on hemagglutinin (HA). However, antibody responses to neuraminidase (NA) have been established as an independent correlate of protection. Here, we introduced the ectodomain of NA into DNA vaccines that as translated dimeric vaccine proteins target antigen-presenting cells (APCs). The targeting was mediated by a scFv specific for MHC class II which is genetically linked to NA via a dimerization motif. A single immunization of BALB/c mice elicited strong and long-lasting NA-specific antibodies that inhibited NA enzymatic activity and reduced viral replication. Vaccine-induced NA immunity completely protected against a homologous influenza virus and out-competed NA immunity induced by a conventional inactivated virus vaccine. The protection was mainly mediated by antibodies, although NA-specific T cells also contributed. Both APC-targeting and antigen bivalency were crucial for vaccine efficacy. The APC-targeted vaccine was potent at low doses of DNA, indicating a dose-sparing effect. Similar results were obtained with NA vaccines that targeted different surface molecules on dendritic cells. Interestingly, the protective efficacy of NA as antigen compared favorably with HA and therefore ought to receive more attention in influenza vaccine research.
 
Back
Top Bottom